Bexagliflozin CAS# 1118567-05-7 贝沙格列净

Bexagliflozin is a potent, selective SGLT2 inhibitor designed to reduce renal glucose reabsorption. In preclinical enzyme assays, it showed high affinity for human SGLT2 (IC₅₀ ~1–2 nM) with >300-fold selectivity over SGLT1. In rodent models of diabetes, oral bexagliflozin produced robust glucosuria and lowered fasting glucose by 25–40%, with parallel reductions in HbA1c after repeated dosing. It also improved insulin sensitivity and reduced body-weight gain in diet-induced obese animals. Toxicology studies in rats and dogs indicated good tolerability and a safety profile consistent with other SGLT2 inhibitors.